Background
==========

Cerebral infarction (or ischemic stroke) is due to localized brain tissue necrosis or cerebral ischemia caused by cerebral blood disorders, resulting from a blockage in the blood vessels that supply blood to the brain \[[@b1-medscimonit-24-1171]--[@b3-medscimonit-24-1171]\]. Cerebral infarction has emerged as a global disease, with increasing incidence and prevalence in different parts of the world \[[@b4-medscimonit-24-1171],[@b5-medscimonit-24-1171]\]. The risk factors of cerebral infarction include gender, age, dyslipidemia, hypertension, diabetes, tobacco smoking, and alcohol abuse \[[@b6-medscimonit-24-1171],[@b7-medscimonit-24-1171]\]. Preventing cerebral infarctions plays an important role in reducing its morbidity and mortality rate.

Apolipoprotein E (ApoE) is a multifunctional protein that plays an important role in lipoprotein metabolism. The human apolipoprotein E (*APOE* gene; OMIM 107741) is located on chromosome 19q13.32 \[[@b8-medscimonit-24-1171],[@b9-medscimonit-24-1171]\]. The three major isoforms of human apolipoprotein E \[E2 (OMIM 107741.0001), E3 (OMIM 107741.0015), and E4 (OMIM 107741.0016)\], as identified by isoelectric focusing, are encoded by three alleles (ɛ2, ɛ3, and ɛ4) \[[@b10-medscimonit-24-1171]--[@b12-medscimonit-24-1171]\].

These three alleles encode different isoforms with various structures and functions, including receptor binding capacity and lipid metabolism based on the presence of either a C or T nucleotide at codons 112 (A) and 158 (B). ApoE2 (Cys112, Cys158), ApoE3 (Cys112, Arg158), and ApoE4 (Arg112, Arg158) are encoded by ɛ2, ɛ3, and ɛ4, respectively. Different combinations of these three alleles generate six genotypes (ɛ2/ɛ2, ɛ3/ɛ3, ɛ2/ɛ3, ɛ3/ɛ4, ɛ2/ɛ4, and ɛ4/ɛ4) \[[@b13-medscimonit-24-1171],[@b14-medscimonit-24-1171]\]. Although the frequency of these alleles/genotypes varies among different populations, *APOE* ɛ3/ɛ3 is the most common genotype, and ɛ3 is the most predominant allele in most populations \[[@b15-medscimonit-24-1171]--[@b20-medscimonit-24-1171]\]. Several studies have demonstrated the association of *APOE* polymorphisms with cardiovascular disease, sea-blue histiocytic disease, lipoprotein glomerulopathy, and Alzheimer disease II \[[@b21-medscimonit-24-1171],[@b22-medscimonit-24-1171]\]. In the present study, we examined the *APOE* allele/genotype frequencies in patients with cerebral infarction and matched controls.

Material and Methods
====================

Participants
------------

This study included 2,047 participants, which consisted of 906 patients \[males: females=601: 305 (or 1.97: 1)\] with cerebral infarction and 1,141 individuals with noncerebral infarction \[males: females=774: 367 (or 2.11: 1)\] as healthy controls. Participants visited Meizhou People's Hospital, located in Guangdong Province, China between February 2016 and April 2017; ages ranged from 13 to 98 years. The study protocol was approved by the Ethics Committee of Meizhou People's Hospital (Huangtang Hospital), Meizhou Hospital Affiliated to Sun Yat-sen University. Written informed consent was obtained from all participants prior to enrollment in the study.

Plasma lipid measurements
-------------------------

Approximately 3 mL of blood was collected from each study participant and the plasma was separated and stored at --80°C until analysis. Plasma levels of triglyceride, total cholesterol, high density lipoprotein, low density lipoprotein, apolipoprotein A1 (Apo-A1), and apolipoprotein B (Apo-B) were measured.

DNA extraction and genotyping
-----------------------------

Blood samples were collected from the study participants and stored in 2-mL vacuum tubes containing ethylenediaminetatraacetic acid (EDTA). Genomic DNA was extracted from each blood sample by using a QIAamp DNA Blood Mini Kit (Qiagen, Germany) following the manufacturer's instructions, and DNA concentration was quantified by using a NanoDrop 2000™ spectrophotometer (ThermoFisher Scientific, Waltham, MA, USA). PCR was performed according to the following protocol: 50°C for two minutes, pre-denaturation at 95°C for 15 minutes, followed by 45 cycles at 94°C for 30 seconds and 65°C for 45 seconds. The amplified products were detected by using an *APOE* Gene typing Detection kit (gene-chip assay) (Sinochips Bioscience Co., Ltd., Zhuhai, Guangdong, China).

Statistical analysis
--------------------

SPSS statistical software version 19.0 was used for data analysis. The data were expressed as the mean ±SD. Regression analysis was used assess the interactions between *APOE* genotypes and various factors. The chi-square test and ANOVA were used to analyze the association between specific *APOE* genotypes and clinical characteristics. A value of *p*\<0.05 was considered statistically significant.

Results
=======

A total of 906 Chinese patients, consisting of 601 men (66.34%) and 305 women (33.66%), and 1,141 controls, comprising 774 men (67.84%) and 367 women (32.16%), were recruited into the study. The patients' mean age was 67.54±12 years, whereas the mean age of the control participants was 62.88±15.10 years. Most of the study participants were from Southern China, including seven areas of Meizhou City, Guangdong Province and some regions of Jiangxi Province. The characteristics of the patient and control groups are presented in [Table 1](#t1-medscimonit-24-1171){ref-type="table"}. Comparison between the patients and the controls indicated statistically significant variances in the clinical parameters of cerebral infarction, which included age, hypertension, hypercholesterolemia, triglycerides, total cholesterol, low density lipoprotein, apolipoprotein A1, and apolipoprotein B, except for high-density lipoprotein and smoking.

The distribution and frequencies of the *APOE* genotypes and alleles in the patient and control groups are summarized in [Table 2](#t2-medscimonit-24-1171){ref-type="table"}. Genotype ɛ3/ɛ3 was the most common type in both groups (56.95% of patients and 66.87% of controls), followed by genotype ɛ2/ɛ3 (22.85% of patients and 17.27% of controls), and ɛ3/ɛ4 (10.82% of patients and 12.01% of controls). Allele ɛ3 was the most common allele (patients: 73.79% of patients and 81.85% of controls), followed by allele ɛ2 (15.67% of patients and 10.43% of controls) and allele ɛ4 (10.54% of patients and 8.06% of controls).

Comparison between carriers and non-carriers in terms of genotype ɛ3/ɛ3 indicated that its frequency was significantly higher in the control group compared to the patient group (*p*\<0.001, OR 0.656, 95% CI 0.526--0.817 in males and *p*=0.008, OR 0.654, 95% CI 0.477--0.896 in females). A statistically significant variance in genotype ɛ2/eɛ4 was also determined to be statistically significant (*p* \< 0.001, OR 3.042, 95% CI 1.798--5.148 in males and *p*=0.007, OR 2.775, 95% CI 1.293--5.956 in females). The variance in genotype ɛ2/ɛ3 between male patients and the control group was also statistically significant (*p*=0.009, OR 1.426, 95% CI 1.096--1.855), but not in females. The correlation of various *APOE* genotypes to serum lipid concentrations is presented in [Table 3](#t3-medscimonit-24-1171){ref-type="table"}.

Univariate logistic analysis showed that age (*p*\<0.001, OR 1.022, 95% CI 1.016--1.027 in males and *p*\<0.001, OR 1.031, 95% CI 1.017--1.045 in females), hypertension (*p*\<0.001, OR 4.447, 95% CI 3.887--5.088 in males and *p*\<0.001, OR 3.899, 95% CI 2.738--5.554 in females), hypercholesterolemia (*p*\<0.001, OR 2.733, 95% CI 2.270--3.290 in males and *p*\<0.001, OR 3.188, 95% CI 2.048--4.964 in females), low density lipoprotein (*p*\<0.001, OR 2.093, 95% CI 1.725--2.539 in males and *p*\<0.001, OR 2.439, 95% CI 1.638--3.631 in females), ApoA1/ApoB (*p*\<0.001, OR 1.634, 95% CI 1.385--1.927 in males and *p*=0.023, OR 1.675, 95% CI 1.074--2.613 in females) were determined to be significant risk factors for cerebral infarction in male and female patients ([Table 4](#t4-medscimonit-24-1171){ref-type="table"}). Additionally, diabetes mellitus (*p*=0.005, OR 1.267, 95% CI 1.073--1.496) and triglyceride levels (*p*\<0.001, OR 1.111, 95% CI 1.052--1.172) were significant risk factors for cerebral infarction in males, but not in females, whereas high-density lipoprotein levels (*p*=0.008, OR 0.698, 95% CI 0.536--0.908) were a favorable factor for cerebral infarction in males, but not in females. The favorable factors for cerebral infarction that were associated with the *APOE* ɛ3/ɛ3 and ɛ3/ɛ4 genotypes were statistically significant in males (*p*\<0.001, OR 0.393, 95% CI 0.237--0.653 and *p*\<0.001, OR 0.376, 95% CI 0.221--0.637, respectively).

Discussion
==========

In the Chinese population, the predominant genotype is ɛ3/ɛ3, whereas the most common allele is ɛ3 \[[@b18-medscimonit-24-1171],[@b23-medscimonit-24-1171]--[@b26-medscimonit-24-1171]\]. In the present investigation, genotype ɛ3/ɛ3 accounted for 62.48% of the genotypes observed in the Chinese population, followed by ɛ2/ɛ3 (19.74%), ɛ3/ɛ4 (11.48%), ɛ2/ɛ4 (4.88%), ɛ4/ɛ4 (0.98%), and ɛ2/ɛ2 (0.44%). Our results also confirmed the findings of previous research studies.

In the present study, the ɛ2/ɛ4 genotype was found to have a higher prevalence in male and female patients, and was thus considered as a risk factor for cerebral infarction. The ɛ3/ɛ3 genotype had a lower prevalence in patients than controls, thereby suggesting its potential protective role. In the male group, participants with the ɛ3/ɛ3 genotype had lower levels of serum total cholesterol and low density lipoprotein. In the female group, participants with the ɛ3/ɛ3 genotype had lower levels of serum triglyceride, total cholesterol, and low density lipoprotein. These findings suggest that the ɛ3/ɛ3 genotype is a protective factor of cerebral infarction. Univariate logistic analysis demonstrated that the *APOE* ɛ3/ɛ3 and ɛ3/ɛ4 genotypes play a protective role in cerebral infarction in Chinese men, but not in women.

Additionally, statistically significant variances in the distribution and frequencies of the ɛ2/ɛ3 and ɛ2/ɛ4 genotypes in men and ɛ2/ɛ4 genotype in women between patients and controls were observed. However, univariate logistic analysis indicated that these genotypes had no association with cerebral infarction. This may be because our sample size was not large enough. The prevalence of risk factors in this non cerebral infarction group was high, particularly that of total cholesterol. This form of selection could explain why logistic analysis showed that total cholesterol is not a risk factor for cerebral infarction. Future studies involving a higher number of study participants, including patients and healthy control subjects, can solve this problem. And further studies with a large sample size are necessary to confirm our findings.

Cerebral infarction is result of complex interactions involving various environmental and genetic factors \[[@b27-medscimonit-24-1171]\]. *APOE* polymorphisms seem to be very good candidates in studying the interplay between genetic and acquired risk factors. Future large-scale studies involving patients that will elucidate the pathophysiological pathways of cerebral infarction may lead to new insights and treatments for this particular cardiovascular disorder.

Conclusions
===========

Statistically significant variances in the distribution and frequencies of *APOE* genotypes were observed between the patients with cerebral infarction and control participants. The present study demonstrated that the *APOE* ɛ3/ɛ3 and ɛ3/ɛ4 genotypes play a protective role for cerebral infarction in Chinese men, but not in women. Additionally, the ɛ2/ɛ4 genotype may be a potential risk factor for cerebral infarction in men, whereas the ɛ3/ɛ4 genotype potentially plays a protective role against this disease in women. However, our findings needed further validation in Chinese population in other provinces.
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###### 

Clinical characteristics of Chinese male and female nonstroke controls and patients with cerebral infarction.

                           Males         Females                                             
  ------------------------ ------------- ------------- --------- ------------- ------------- ---------
  Number of participants   601           774                     305           367           
  Age, years               66.23±12.12   62.14±15.28   \<0.001   70.11±11.35   64.04±15.34   \<0.001
  HTN                      399 (66.39)   210 (27.13)   \<0.001   210 (68.85)   119 (32.42)   \<0.001
  H/C                      195 (32.45)   87 (11.24)    \<0.001   111 (36.39)   54 (14.71)    \<0.001
  TG, mmol/L               1.714±1.439   1.498±2.012   0.026     1.770±1.223   1.522±1.331   0.013
  TC, mmol/L               4.856±1.195   4.335±1.607   \<0.001   5.242±1.300   4.729±1.546   \<0.001
  LDL, mmol/L              3.009±0.935   2.491±1.041   \<0.001   3.176±0.963   2.724±1.182   \<0.001
  Apo-A1, g/L              1.008±0.213   0.911±0.303   \<0.001   1.063±0.258   0.974±0.305   \<0.001
  Apo-B, g/L               0.975±0.284   0.833±0.300   \<0.001   1.031±0.301   0.919±0.369   \<0.001
  Apo-A1/Apo-B             1.113±0.391   1.222±0.587   \<0.001   1.110±0.413   1.183±0.525   0.047

Values for age expressed as the mean ±SD. Numbers in parentheses are percentages. HTN -- hypertension; H/C -- hypercholesterolemia; TG -- triglycerides; TC -- total cholesterol; LDL -- low-density lipoprotein; Apo-A1 -- apolipoprotein A1; Apo-B -- apolipoprotein B.

###### 

Genotypes and allele distribution in Chinese case and control groups.

  Genotype      ɛ2/ɛ2          ɛ2/ɛ3            ɛ2/ɛ4          ɛ3/ɛ3          ɛ3/ɛ4          ɛ4/ɛ4        p values
  ------------- -------------- ---------------- -------------- -------------- -------------- ------------ -----------------------------------------
  Total                                                                                                   
   Cases        4 (0.44%)      207 (22.85%)     69 (7.62%)     516 (56.95%)   98 (10.82%)    12 (1.32%)   \< 0.001
   Controls     5 (0.43%)      197 (17.27%)     31 (2.72%)     763 (66.87%)   137 (12.01%)   8 (0.70%)    
  Males                                                                                                   
   Cases        2 (0.33%)      142 (23.63%)     47 (7.82%)     341 (56.74%)   61(10.15%)     8 (1.33%)    \< 0.001
   Controls     1 (0. 13%)     138 (17.83%)     21 (2.71%)     516 (66.67%)   92 (11.89%)    6 (0.77%)    
   ɛ2/ɛ3        --             142/138          --             --             --             --           P=0.009 (OR 1.426, 95% CI 1.096--1.855)
   ɛ2/ɛ4        --             --               47/21          --             --             --           \<0.001 (OR 3.042, 95% CI 1.798--5.148)
   ɛ3/ɛ3        --             --               --             341/516        --             --           \<0.001 (OR 0.656, 95% CI 0.526--0.817)
  Females                                                                                                 
   Cases        2 (0.66%)      65 (21.31%)      22 (7.21%)     175 (57.38%)   37 (12.13%)    4 (1.31%)    0.018
   Controls     4 (1.09%)      59 (16.08%)      10 (2.72%)     247 (67.30%)   45 (12.26%)    2 (0.54%)    
   ɛ2/ɛ4        --             --               22/10          --             --             --           P=0.007 (OR 2.775, 95% CI 1.293--5.956)
   ɛ3/ɛ3        --             --               --             175/247        --             --           P=0.008 (OR 0.654, 95% CI 0.477--0.896)
  **Alleles**   ɛ2             ɛ3               ɛ4                                                        
   Total                                                                                                  
   Cases        284 (15.67%)   1,337 (73.79%)   191 (10.54%)                                              \<0.001
   Controls     238 (10.43%)   1,860 (81.51%)   184 (8.06%)                                               
  Males                                                                                                   
   Cases        193 (16.06%)   885 (73.63%)     124 (10.32%)                                              \<0.001
   Controls     161 (10.40%)   1,262 (81.52%)   125 (8.07%)                                               
  Females                                                                                                 
   Cases        91 (14.92%)    452 (74.10%)     67 (10.98%)                                               P=0.005
   Controls     77 (10.49%)    598 (81.47%)     59 (8.04%)                                                

###### 

Association of *APOE* genotypes with serum lipid concentrations of Chinese patients with cerebral infarction.

            APOE          TG, mmol/L    TC, mmol/L    HDL, mmol/L   LDL, mmol/L
  --------- ------------- ------------- ------------- ------------- -------------
  Males     ɛ2/ɛ3                                                   
             Cases        1.838±1.711   4.633±1.146   1.138±0.412   2.905±0.905
             Controls     1.793±3.040   4.289±1.906   1.144±0.776   2.500±1.139
             *P* values   0.881         0.068         0.935         \<0.001
            ɛ2/ɛ4                                                   
             Cases        2.105±1.179   4.972±1.098   1.016±0.215   3.286±0.872
             Controls     1.179±0.609   4.091±1.699   0.980±0.433   2.589±1.397
             *P* values   0.001         0.013         0.650         0.015
            ɛ3/ɛ3                                                   
             Cases        1.589±1.203   4.905±1.200   1.158±0.324   3.002±0.951
             Controls     1.477±1.855   4.321±1.562   1.135±0.576   2.467±0.995
             *P* values   0.323         \<0.001       0.498         \<0.001
  Females   ɛ2/ɛ4                                                   
             Cases        1.781±0.950   4.942±1.095   1.209±0.266   3.134±0.916
             Controls     2.119±1.610   5.658±1.107   1.331±0.328   3.260±0.494
             *P* values   0.462         0.098         0.273         0.687
            ɛ3/ɛ3                                                   
             Cases        1.696±1.182   5.273±1.309   1.262±0.302   3.142±0.995
             Controls     1.450±1.180   4.648±1.391   1.187±0.352   2.665±1.044
             *P* values   0.035         \<0.001       0.024         \<0.001

###### 

Logistic regression analysis of factors that influence Chinese patients with cerebral infarction.

  Variable       Males   Females                                         
  -------------- ------- -------------- --------- ------- -------------- ---------
  Age            1.022   1.016--1.027   \<0.001   1.031   1.017--1.045   \<0.001
  HTN            4.447   3.887--5.088   \<0.001   3.899   2.738--5.554   \<0.001
  H/C            2.733   2.270--3.290   \<0.001   3.188   2.048--4.964   \<0.001
  DM             1.267   1.073--1.496   0.005                            
  TG             1.111   1.052--1.172   \<0.001                          
  TC             0.672   0.567--0.797   \<0.001   0.662   0.466--0.830   \<0.001
  HDL            0.698   0.536--0.908   0.008                            
  LDL            2.093   1.725--2.539   \<0.001   2.439   1.638--3.631   \<0.001
  Apo-A1/Apo-B   1.634   1.385--1.927   \<0.001   1.675   1.074--2.613   0.023
  *APOE*                                                                 
   e3/e3         0.393   0.237--0.653   \<0.001                          
   e3/e4         0.376   0.221--0.637   \<0.001                          
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